ArticleBMC cancer2025
Plasma lipidomics for biomarker identification in non-muscle invasive bladder cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder cancer is a high-incidence malignant tumor in the world. Currently available potential biomarkers lack sufficient diagnostic accuracy, underscoring the need for novel biomarkers. Lipid metabolites have emerged as promising candidates for diagnosing malignant tumors in recent years. Few studies explored the potential value of lipids in bladder cancer. Our study investigated plasma lipid metabolism markers in non-muscle invasive bladder cancer (NMIBC) using liquid chromatography-high resolution mass spectrometry (LC-HRMS).
methodsOverall, 214 cases were included, with 106 NMIBC patients as NMIBC group and 108 healthy adults as control group. Plasma lipids were profiled using LC-HRMS to distinguish NMIBC group from control group, low-grade NMIBC group from control group and low-grade NMIBC group from high-grade NMIBC group.
resultsApparent separation was observed between NMIBC group and control group. Hydroxy fatty acids, O-TAG, O-LPG and hydrocarbons metabolites were significantly enriched in NMIBC group. A Lipids panel of PE(14:1/20:0), PE(18:2/16:0) and 19-methyl-heneicosanoic acid was used to conduct a predictive model of NMIBC group and control group. The model showed acceptable accuracy for NMIBC diagnosis with the area under the curve (AUC) of 0.88 and 0,82 for training and validation cohorts, respectively, especially for the low-grade NMIBC diagnosis with the AUC of 0.81. For low- and high-grade NMIBC distinction, a panel of four lipids achieved good performance with the AUC value of 0.815 (10-fold cross validation: 0.77; leave-one-out validation (LOOCV):0.77).
conclusionLipid profiles differed significantly between patients with non-muscle invasive bladder cancer (NMIBC) and healthy adults. The identified lipid biomarkers demonstrated high discriminatory accuracy in diagnosing and grading NMIBC, indicating their promising clinical potential for both detection and monitoring of bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.